Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649847 | 0.94 | KCNK3 (0.55) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL584450 | 0.94 | KCNK3 (0.55) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL16053284 | 0.94 | KCNK3 (0.55) | KCNK3KCNK9JAK2JAK1GPR119 | |
| Hydrochloric Acid SCHEMBL6095348 | 0.92 | KCNK3 (0.54) | KCNK3KCNK9JAK2JAK1GPR119 | |
| Hydrochloric Acid SCHEMBL6093599 | 0.92 | KCNK3 (0.54) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL16376097 | 0.86 | KCNK3 (0.56) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL3642479 | 0.85 | JAK2 (0.56) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL3335624 | 0.85 | JAK2 (0.62) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL16963755 | 0.85 | JAK2 (0.56) | KCNK3KCNK9JAK2JAK1GPR119 | |
| SCHEMBL8056077 | 0.85 | JAK2 (0.58) | JAK2JAK1GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1047695-B1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1192154-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| US-6492382-B1 | Dried or frozen pharmaceutical preparation containing a class III antiarrhythmic compound | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-1192154-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| US-6291475-B1 | 3,7-DIAZABICYCLO(3.3.1)NONANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| WO-2000076999-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| EP-1043997-A1 | A DRIED OR FROZEN PHARMACEUTICAL PREPARATION CONTAINING A CLASS III ANTIARRHYTHMIC COMPOUND | AstraZeneca AB (SE) | 2000-10-18 | — | — | EP | disclosed |
| WO-2000021533-A1 | A DRIED OR FROZEN PHARMACEUTICAL PREPARATION CONTAINING A CLASS III ANTIARRHYTHMIC COMPOUND | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | KCNK3 235/4885KCNK9 153/4885JAK2 3252/4885 |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | KCNK3 1025/4885KCNK9 1041/4885JAK2 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.